Encompass Health (EHC) Q4 2025 earnings review
Operating Leverage Shines as Capacity Expansion Accelerates
Encompass Health capped 2025 with a textbook 'beat and raise' quarter. While revenue grew nearly 10% driven by robust demand and pricing, the real story was operational efficiency—Adjusted EBITDA jumped almost 16% as labor costs moderated. Management is pressing its advantage, forecasting aggressive capacity expansion for 2026 with 8 new hospitals and ~175 bed additions. The balance sheet remains pristine (1.9x leverage), allowing for continued growth investment and shareholder returns.
🐂 Bull Case
The 'Silver Tsunami' provides a durable floor for demand. The 75+ population is growing at 4% annually. This drove a 5.3% increase in total discharges in Q4, despite tough prior-year comparisons.
Salaries and Benefits (SWB) dropped to 51.9% of revenue from 53.9% a year ago. Management has successfully navigated the post-pandemic labor market, reducing reliance on expensive contract labor while maintaining capacity.
🐻 Bear Case
While total growth remains high due to new openings, same-store discharge growth has cooled from 4.7% in Q2 to 3.2% in Q4. As the portfolio matures, maintaining high-single-digit volume growth becomes increasingly capital intensive.
The Review Choice Demonstration (RCD) expands to Texas in March 2026 and California in May 2026. While affirmation rates are high (93% in Alabama), the administrative burden of pre-claim reviews adds friction to operations.
⚖️ Verdict: 🟢🟢
Strong Buy. Encompass is a consistent compounder executing perfectly in a favorable demographic environment. With leverage at 1.9x and cash flow surging, they control their own destiny regardless of the macro environment.
Key Themes
Aggressive Capacity Expansion
Management is not slowing down. 2025 saw 8 new hospitals and 127 bed additions. 2026 guidance targets another 8 new hospitals (389 beds) plus ~175 bed additions to existing facilities. This aggressive capital deployment is the primary engine for double-digit earnings growth.
Pricing Power & Payer Mix
Net patient revenue per discharge grew 4.1% YoY to $22,273. This outpaces the 3.0-3.5% labor inflation guidance, preserving margins. The company anticipates a ~3.0% Medicare pricing increase and 2.0-3.0% managed care pricing increase in 2026.
Same-Store Growth Normalization
Decelerating. Same-store discharge growth has trended down from 4.8% (24Q2) and 6.8% (24Q3) to 3.2% in 25Q4. While 3%+ is healthy, the 'COVID rebound' and acute-care backlog benefits have fully normalized, meaning future growth relies heavily on new builds rather than organic squeezes.
TEAM Payment Model
CMS is launching the Transforming Episode Accountability Model (TEAM) in 2026. While mandatory for selected acute care hospitals, Encompass views this neutrally to positively. With 89 hospitals in TEAM markets, their history with BPCI/CJR bundles suggests they can manage the data requirements without revenue cycle disruption.
Pre-Opening Drag
The aggressive growth comes with a P&L penalty. 2026 guidance assumes $18-$22 million in net pre-opening and ramp-up costs. While necessary for long-term growth, this creates a persistent drag on short-term margin expansion.
Other KPIs
Accelerating. Up 23.6% YoY. Cash conversion remains excellent, allowing the company to fund its heavy CapEx plans ($695M-$755M for 2026) while paying dividends and repurchasing shares ($76.3M bought back in Q4).
Stable/Improving. Down from 2.2x at year-end 2024. This is below the typical 2.5x-3.0x range for similar healthcare REIT/Operator models, giving them significant 'dry powder' for M&A or larger buybacks.
Improving. Decreased 200 basis points from 53.9% in Q4 2024. This is a critical metric indicating that revenue growth (pricing + volume) is outpacing labor inflation.
Guidance
Stable/Decelerating. The midpoint implies ~8.1% YoY growth, compared to 10.5% growth achieved in 2025. This reflects a normalization of volume growth and stable pricing environments.
Decelerating. Midpoint growth of ~7.3%, compared to 14.9% in 2025. Margin expansion is expected to pause or compress slightly due to the $18-22M drag from new hospital openings and ramp-up costs.
Decelerating. Midpoint growth of ~9.2% vs 23.0% in 2025. Still a healthy return profile, driven by EBITDA growth and share repurchases (share count guided to ~102M, flat to slightly down).
Key Questions
Same-Store Ceiling
With same-store discharge growth settling near 3%, are we returning to the pre-pandemic norm of 2-3%, or do you see structural reasons (acuity mix, market share gains) to sustain 4%+?
RCD Expansion Friction
As the Review Choice Demonstration moves into Texas (24 hospitals) and California (3 hospitals) in H1 2026, have you factored any specific volume disruption or administrative cost spikes into the guidance?
TEAM Model Economics
Can you elaborate on the potential financial impact of the TEAM mandatory bundle model starting in 2026? Does the 'upside/downside risk' present a material variance to your 2026 outlook?
Capital Allocation Shift
With leverage at 1.9x and cash flow surging, why not increase the buyback pace more aggressively beyond the current run rate, given the stock's valuation?